Oragenics, Inc is a biotechnology business based in the US. Oragenics shares (OGEN) are listed on the NYSE MKT and all prices are listed in US Dollars. Oragenics employs 7 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Oragenics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – OGEN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Oragenics stock price (NYSE MKT: OGEN)Use our graph to track the performance of OGEN stocks over time.
Oragenics shares at a glance
|Latest market close||$0.72|
|52-week range||$0.38 - $1.62|
|50-day moving average||$0.69|
|200-day moving average||$0.85|
|Wall St. target price||$2.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.51|
Buy Oragenics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Oragenics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Oragenics price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||5.88%|
|3 months (2021-04-30)||-10.00%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-62.94%|
|Return on equity TTM||-108.1%|
|Market capitalisation||$87.3 million|
TTM: trailing 12 months
Shorting Oragenics shares
There are currently 2.7 million Oragenics shares held short by investors – that's known as Oragenics's "short interest". This figure is 4.9% down from 2.9 million last month.
There are a few different ways that this level of interest in shorting Oragenics shares can be evaluated.
Oragenics's "short interest ratio" (SIR)
Oragenics's "short interest ratio" (SIR) is the quantity of Oragenics shares currently shorted divided by the average quantity of Oragenics shares traded daily (recently around 1.2 million). Oragenics's SIR currently stands at 2.27. In other words for every 100,000 Oragenics shares traded daily on the market, roughly 2270 shares are currently held short.
However Oragenics's short interest can also be evaluated against the total number of Oragenics shares, or, against the total number of tradable Oragenics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oragenics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Oragenics shares in existence, roughly 20 shares are currently held short) or 0.0239% of the tradable shares (for every 100,000 tradable Oragenics shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oragenics.
Find out more about how you can short Oragenics stock.
Oragenics share dividends
We're not expecting Oragenics to pay a dividend over the next 12 months.
Have Oragenics's shares ever split?
Oragenics's shares were split on a 1:10 basis on 21 January 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oragenics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Oragenics shares which in turn could have impacted Oragenics's share price.
Oragenics share price volatility
Over the last 12 months, Oragenics's shares have ranged in value from as little as $0.3826 up to $1.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Oragenics's is 0.2775. This would suggest that Oragenics's shares are less volatile than average (for this exchange).
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc.
Stocks similar to Oragenics
Oragenics in the news
62 Biggest Movers From Yesterday
50 Stocks Moving In Wednesday's Mid-Day Session
28 Stocks Moving in Wednesday's Pre-Market Session
Frequently asked questionsWhat percentage of Oragenics is owned by insiders or institutions?
Currently 2.745% of Oragenics shares are held by insiders and 7.883% by institutions. How many people work for Oragenics?
Latest data suggests 7 work at Oragenics. When does the fiscal year end for Oragenics?
Oragenics's fiscal year ends in December. Where is Oragenics based?
Oragenics's address is: 4902 Eisenhower Boulevard, Tampa, FL, United States, 33634 What is Oragenics's ISIN number?
Oragenics's international securities identification number is: US6840233026 What is Oragenics's CUSIP number?
Oragenics's Committee on Uniform Securities Identification Procedures number is: 684023104
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert